Prescriber Scope of Practice for ADHD in Florida

You’ve built a successful ADHD practice, but your schedule is maxed out and you’re turning away patients who need care. Or maybe you’re considering telehealth to reach underserved areas, but you’re not sure if you can legally prescribe stimulants over video visits. You’re not alone — these are the top questions we hear from psychiatrists and psychiatric nurse practitioners every week.

Here’s the reality: Yes, you can prescribe ADHD medications via telehealth in 2026, but the rules are complex and changing. Federal regulations, state-specific laws, and your provider type all factor into what you can prescribe, to whom, and under what conditions. Get it wrong, and you risk DEA scrutiny or state board action. Get it right, and telehealth opens a massive opportunity to grow your practice while serving patients who desperately need access to care.

This guide cuts through the confusion. We’ll walk you through the federal DEA rules (including the 2026 extension and upcoming permanent regulations), break down the laws in six key states (California, Texas, Florida, New York, Pennsylvania, and Illinois), and explain exactly what psychiatrists versus PMHNPs can do in each jurisdiction. Whether you’re considering joining a telehealth platform or just want to add virtual ADHD visits to your current practice, you’ll have the clarity you need to move forward confidently.

Federal Law: Can You Prescribe Stimulants via Telehealth Without an In-Person Visit?

Short answer: Through December 31, 2026, yes — under the current federal extension. After that, new DEA rules will govern telehealth prescribing permanently.

The Ryan Haight Act and COVID-Era Flexibilities

Before COVID-19, the Ryan Haight Online Pharmacy Consumer Protection Act (2008) effectively banned prescribing any controlled substance — including ADHD medications — via telehealth without at least one in-person medical evaluation. There were narrow exceptions (treating patients in DEA-registered facilities, for instance), but telehealth-only ADHD treatment was essentially illegal federally.

In March 2020, the DEA exercised emergency authority to waive the in-person exam requirement for the duration of the Public Health Emergency. This allowed providers to prescribe Schedule II controlled substances (Adderall, Ritalin, Vyvanse, etc.) after a video consultation with a new patient, with no prior in-person visit required.

When the PHE ended in May 2023, many feared telehealth prescribing would abruptly halt. Instead, the DEA and HHS have issued four consecutive extensions. The most recent (January 2026) extends the telehealth flexibility through December 31, 2026, allowing continued prescribing of Schedule II–V controlled substances via telemedicine without an initial in-person exam.

What This Means for Your Practice Right Now

Through the end of 2026, you can:

• Conduct a video evaluation (two-way, real-time audiovisual) with a new ADHD patient
• Diagnose ADHD and initiate stimulant medication treatment
• Issue prescriptions electronically to the patient’s pharmacy
• Continue follow-up visits and refills via telehealth

You cannot:

• Prescribe based solely on an online questionnaire without live interaction (the DEA requires real-time communication)
• Use audio-only calls for initial controlled substance prescriptions (video is required for Schedule II stimulants; audio-only was permitted only for buprenorphine in limited OUD treatment contexts)

You must still follow all other controlled substance rules: legitimate medical purpose, documented evaluation meeting the standard of care, DEA registration in the patient’s state, and compliance with state PDMP (Prescription Drug Monitoring Program) requirements.

What’s Coming: DEA’s Permanent Telemedicine Rules

The DEA is finalizing three new regulations to replace the temporary extensions. In January 2025, the agency previewed key elements:

1. Telemedicine Special Registration
The DEA will create a new registration category allowing providers to prescribe controlled substances via telehealth without an in-person exam. To qualify, you’ll need to:

• Obtain the special DEA registration (in addition to your standard DEA number)
• Check a nationwide PDMP database (the DEA is building a centralized data hub)
• Verify patient identity during the video consultation
• Follow strict documentation standards

This registration will be voluntary initially but will likely become the primary pathway for telehealth prescribing once the 2026 extension expires.

2. Platform Registration Requirements
For the first time, the DEA will require telehealth platforms themselves to register with the agency. This corporate-level oversight aims to prevent ‘pill mill’ operations and ensure platform compliance with prescribing safeguards.

3. Established Patient Exception
If you’ve seen a patient in person at least once (even at a previous practice or through a colleague in a group), you can continue prescribing via telehealth without additional requirements. The special registration and PDMP mandates apply primarily to patients you’ve never seen face-to-face.

Timeline Uncertainty: The DEA has not published final rule text or effective dates. Based on the agency’s statements about avoiding disruptions in patient access, expect the new framework to take effect in early-to-mid 2027, giving providers time to obtain special registrations before the current extension expires.

Bottom line for providers: Plan to obtain the DEA telemedicine special registration when it becomes available in 2026. Until then, operate under the current extension with confidence that you’re compliant federally — just ensure you’re using video, documenting properly, and checking state PDMPs.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Breakdown: Where You Can Prescribe ADHD Meds via Telehealth

Federal law sets the floor, but states can (and do) add their own requirements or restrictions. Here’s what you need to know for our six priority states, focusing on the rules that actually affect your day-to-day practice.

California: Progressive, with PDMP Requirements

Can you prescribe ADHD meds via telehealth? Yes, without restriction.

California law explicitly allows prescribing ‘dangerous drugs’ (including controlled substances) via telehealth if the evaluation meets the standard of care. The state’s Business & Professions Code considers a telehealth exam — even asynchronous methods in some cases — sufficient for prescribing. There’s no state requirement for an in-person visit beyond federal law.

PMHNP scope: California is transitioning to Full Practice Authority for nurse practitioners through 2026. Experienced NPs who complete 4,600 hours under physician supervision can practice independently, including prescribing Schedule II stimulants. New grad NPs still need supervising physician agreements initially, but this independence pathway makes California attractive for NP-led telehealth.

Critical compliance step: You must check the CURES database (California’s PDMP) before prescribing any Schedule II-IV controlled substance for the first time, and at least every four months for ongoing therapy. This is not optional — it’s a legal requirement enforced by the Medical Board.

Licensing: No shortcuts. You need a full California medical or nursing license. California is not part of the Interstate Medical Licensure Compact, and there’s no special telehealth registration for out-of-state providers. Budget 3-6 months for licensure if you’re coming from another state.

Provider economics: California has the highest concentration of ADHD patients and among the highest reimbursement rates. The state’s telehealth parity law means insurance must cover virtual visits at the same rate as in-person. For cash-pay, patients in major metros (SF, LA, San Diego) are accustomed to paying $200-300+ for psychiatric visits.

Texas: Physicians Only for Stimulants

Can you prescribe ADHD meds via telehealth? Yes, if you’re a physician. No, if you’re a nurse practitioner or PA.

Texas allows telehealth for mental health treatment, and there’s no state ban on tele-prescribing stimulants for ADHD. However, Texas has one of the nation’s most restrictive rules for APRNs: nurse practitioners and physician assistants cannot prescribe Schedule II controlled substances in outpatient settings. Period.

The only exceptions are hospital inpatients (≥24 hours), hospice patients, or emergency medication orders in a hospital ER. Outpatient ADHD treatment doesn’t qualify. Texas Board of Nursing guidance is explicit: ‘There are no other outpatient settings at which APRNs may prescribe Schedule II controlled substances.’

What this means practically: If you’re a PMHNP considering Texas, you’ll need a physician to write all stimulant prescriptions, even if you conduct the evaluation. If you’re a psychiatrist, you have full authority — just ensure you’re licensed in Texas or use the IMLC (Texas is a member state) to expedite licensure.

PDMP requirements: Texas mandates checking the PMP for opioids, benzodiazepines, barbiturates, and carisoprodol — stimulants aren’t technically required, but checking for ADHD medications is best practice to document due diligence.

Provider opportunity: Texas has massive ADHD treatment gaps, especially in rural areas. The state’s telehealth laws are friendly (a physician-patient relationship can be established via video), but the NP restriction means you’ll compete primarily with other physicians unless you build a collaborative model.

Florida: Explicit Psychiatric Exception

Can you prescribe ADHD meds via telehealth? Yes — Florida law explicitly allows it.

This is one of the clearest state rules: Florida Statutes §456.47 generally prohibits prescribing Schedule II controlled substances via telehealth except for (1) treatment of psychiatric disorders, (2) inpatient hospital care, (3) hospice, or (4) nursing home residents.

ADHD treatment falls squarely under ‘psychiatric disorder,’ so you’re covered. A Florida-licensed psychiatrist or PMHNP can prescribe stimulants after a video evaluation, no in-person visit required.

PMHNP scope: Florida requires PMHNPs to practice under a protocol agreement with a supervising psychiatrist. However, psychiatric nurses with proper credentials (master’s in psychiatric nursing, 2+ years post-grad psych experience) are exempt from the 7-day limit on Schedule II prescriptions that applies to other NPs. You can write full 30-day prescriptions and refills.

Out-of-state provider option: Florida offers an out-of-state telehealth registration that allows providers licensed in another state to treat Florida patients via telehealth without obtaining a full Florida license. Requirements include an active, unrestricted license in your home state, clean disciplinary record for 5 years, and malpractice insurance. Since ADHD treatment qualifies under the psychiatric exception, an out-of-state psychiatrist registered for telehealth in Florida can legally prescribe stimulants to Florida patients.

PDMP compliance: You must check Florida’s E-FORCSE database before prescribing controlled substances to patients age 16 or older. Exceptions exist for non-refillable 3-day supplies, but for ongoing ADHD treatment, the PDMP check is mandatory.

Provider economics: Florida’s telehealth market is growing rapidly, with significant demand in underserved areas outside Miami/Tampa/Orlando. The out-of-state registration option makes it easier to add Florida patients without the 6-12 month licensing process.

New York: Recently Aligned with Federal Law

Can you prescribe ADHD meds via telehealth? Yes, as of May 2025.

New York previously had regulations that mirrored the federal Ryan Haight Act, requiring an in-person exam for controlled substance prescriptions. In May 2025, the state updated its rules to explicitly allow prescribing controlled substances via telehealth when consistent with federal law.

Practically, this means as long as the DEA extension is in effect (through 2026), New York allows telehealth ADHD prescribing. When the DEA’s permanent rules take effect, New York will require compliance with those as well — the state intentionally aligned its law to avoid being more restrictive than federal rules.

PMHNP scope: New York is relatively progressive for NPs. After 3,600 hours of clinical experience, NPs can practice independently without a written collaborative agreement (though they must maintain a collaborative relationship with a physician). PMHNPs can prescribe Schedule II stimulants with the same authority as physicians, no quantity limits.

Unique advantage: New York allows prescribing up to a 90-day supply of stimulants for ADHD if the prescription indicates it’s for ‘minimal brain dysfunction’ (the older term for ADHD) by using code ‘B’ on the prescription. This reduces the administrative burden of monthly refills for stable patients and improves patient compliance.

PDMP requirements: You must check New York’s I-STOP/PMP registry before prescribing any Schedule II, III, or IV controlled substance. This check is required for every stimulant prescription — not just the initial one. New York also mandates electronic prescribing for all controlled substances (no paper prescriptions).

Licensing: New York requires a full state license — no telehealth registration option and not part of the IMLC. However, the state’s large ADHD patient population and strong telehealth reimbursement (including Medicaid coverage) make the licensing investment worthwhile.

Pennsylvania: NP Collaboration Required

Can you prescribe ADHD meds via telehealth? Yes, following federal rules.

Pennsylvania doesn’t have specific telehealth prescribing restrictions beyond federal law. The state’s medical boards have confirmed that a valid patient-provider relationship can be established via telemedicine, and prescribing is acceptable if the encounter meets the standard of care.

PMHNP scope: Pennsylvania is a restricted practice state for NPs. Certified Registered Nurse Practitioners must have a collaborative agreement with a physician and face prescriptive authority limits:

• Schedule II controlled substances: 30-day supply maximum
• Continuation beyond 30 days requires physician approval (the collaborating doctor must OK it)
• The physician must review the NP’s Schedule II prescribing monthly

For ADHD care, this means a PMHNP can initiate treatment and write the first month’s prescription, but the supervising psychiatrist needs to be involved for ongoing therapy. Many practices structure this as periodic case review rather than the physician seeing every patient, but the oversight requirement is real.

Physicians (psychiatrists) have no such restrictions — full prescriptive authority for ADHD medications via telehealth.

PDMP compliance: Pennsylvania law requires checking the state PDMP before prescribing any controlled substance at the start of a new course of treatment, and mandates checking before each opioid or benzodiazepine prescription. While stimulants aren’t explicitly included in the ‘every time’ requirement, best practice is to check the PDMP for each ADHD prescription.

Licensing: Pennsylvania joined the IMLC in 2022, making it easier for out-of-state psychiatrists to obtain a PA license. For NPs, you’ll need a full Pennsylvania nursing license and CRNP certification.

Market opportunity: Pennsylvania has substantial ADHD treatment demand, especially in rural areas, and the state’s embrace of tele-mental health (strong Medicaid coverage) creates opportunities despite the NP collaboration requirements.

Illinois: Path to NP Independence

Can you prescribe ADHD meds via telehealth? Yes, with no state restrictions.

Illinois allows telehealth practice broadly and doesn’t impose barriers to prescribing controlled substances beyond federal law. The state’s 2021 Telehealth Act amendment strengthened access, requiring insurance parity for tele-mental health.

PMHNP scope: Illinois offers two tiers of NP practice:

Under Collaboration:

• NPs need a collaborative agreement with a physician
• Can prescribe a 30-day supply of Schedule II controlled substances
• Any continuation beyond 30 days requires physician approval
• Physician must review the NP’s Schedule II prescribing monthly

Full Practice Authority (FPA):

• After 4,000 hours of clinical practice under collaboration and 250 hours of CE/training, NPs can apply for FPA
• FPA NPs can practice and prescribe independently
• For Schedule II stimulants specifically: No physician consultation required (the law’s consultation requirement applies only to Schedule II narcotics and benzodiazepines — stimulants are non-narcotic Schedule II)

This distinction is huge for telehealth platforms. An Illinois PMHNP with FPA can manage ADHD patients end-to-end, prescribing stimulants without any physician oversight. It’s one of the most favorable regulatory environments for nurse practitioner-led ADHD care.

Licensing requirements: Any provider prescribing controlled substances in Illinois needs:

• Illinois professional license (medical or nursing)
• Illinois Controlled Substance License (separate from DEA registration)
• DEA registration covering Illinois

PDMP: Illinois law mandates documenting a PMP check for each opioid prescription and initial benzodiazepine prescriptions. While not explicitly required for stimulants, checking the Illinois PMP (AWARxE) for ADHD medications is recommended best practice.

Psychiatrists practicing in Illinois (via IMLC or direct licensing) have full prescriptive authority with no special telehealth restrictions.

Psychiatrist vs PMHNP: Who Can Do What?

Psychiatrists (MD/DO)

Federal authority: Full prescriptive authority in all 50 states for Schedule II-V controlled substances, including all ADHD medications. No supervision requirements.

State variations: None for scope of practice. As a psychiatrist, if you’re licensed in a state and have a DEA registration covering that state, you can prescribe ADHD medications via telehealth (subject to the federal rules and that state’s PDMP/telehealth standards).

Licensing strategy:

• Use the IMLC if you’re in a member state to expedite multi-state licensure (21 states participate as of 2026, including Texas, Pennsylvania, Illinois)
• Florida’s out-of-state telehealth registration is a faster alternative to full licensure
• Budget 3-6 months and $1,000-2,000 per state for non-compact states (California, New York)

Practice consideration: You have maximum flexibility. The regulatory complexity is mostly about staying current with federal DEA rules and state PDMP requirements, not scope of practice limitations.

Psychiatric Mental Health Nurse Practitioners (PMHNPs)

Federal authority: Same as psychiatrists — can prescribe Schedule II stimulants in all 50 states where licensed.

State variations: Significant. Your prescriptive authority and supervision requirements depend entirely on state law:

Full Practice Authority States (for ADHD):

• California (for experienced NPs by 2026)
• New York (after 3,600 hours)
• Illinois (with FPA certification after 4,000 hours)

Restricted Practice States:

• Pennsylvania: 30-day limit on Schedule II; physician approval for continuation
• Illinois (without FPA): 30-day limit; physician approval for continuation
• Florida: Must practice under psychiatric protocol; supervising psychiatrist required (but no quantity limit for psychiatric nurses)

Prohibited:

• Texas: Cannot prescribe Schedule II in outpatient settings at all

Strategic implications: If you’re a PMHNP building a telehealth practice, focus on states where you can practice independently or where the collaboration requirements are manageable. New York and California offer the best combination of independence and market size. Florida is attractive despite the supervision requirement because of the out-of-state registration option and large patient population.

For Texas, you’ll need to partner with a psychiatrist or work for an organization that employs physicians to write stimulant prescriptions.

The Economics: Why Telehealth Makes Sense for ADHD Care

Let’s talk about what really matters — can you build a sustainable, profitable practice treating ADHD via telehealth?

The Patient Acquisition Problem

If you’re doing traditional marketing to build an ADHD practice, you’re facing some hard realities:

DIY Marketing Costs:

• SEO: 6-12 months of consistent investment ($2,000-5,000/month for a good agency) before you see meaningful patient flow. Most solo providers don’t have the expertise or patience.
• Google Ads: Mental health keywords cost $15-40+ per click. Factor in that most clicks don’t convert, testing time, and optimization, and you’re looking at $200-400+ per booked patient.
• Directory listings (Psychology Today, Zocdoc): Monthly subscription fees ($100-300) plus competition with hundreds of other providers on the same page. Zocdoc charges per booking ($35-100+), and total monthly costs add up fast.
• Hidden costs: Staff time handling and qualifying leads, no-show rates from cold leads, failed campaigns you have to eat

When you add it all up, acquiring a qualified psychiatric patient through DIY marketing typically costs $200-500+ in total acquisition cost. And that’s if you know what you’re doing and have months to test and optimize.

The Telehealth Platform Model

Platforms like Klarity Health use a pay-per-appointment model. Instead of gambling on marketing channels with uncertain ROI, you pay a standard listing fee only when a pre-qualified patient books an appointment with you.

The value proposition:

• No upfront marketing spend — zero monthly retainers or subscription fees
• Pre-qualified patients matched to your specialty and availability (ADHD-specific referrals)
• No wasted ad spend on clicks that don’t convert
• Built-in infrastructure — telehealth platform, scheduling, insurance credentialing support (no separate platform costs)
• Both insurance and cash-pay patient flow, depending on your preference
• You control your schedule — only pay when you see patients, scale up or down as needed

Economic reality check: If you’re spending $3,000-5,000/month on marketing to fill your schedule, you’re risking that money with no guarantee of results. With a pay-per-appointment platform, you guarantee ROI — you only pay when a patient shows up.

For most providers, especially those starting out or scaling an existing practice, removing the patient acquisition risk entirely is worth the per-appointment fee. You focus on clinical care; the platform handles marketing, vetting, and matching.

Income Potential: Real Numbers

Insurance-based:

• CPT 99214 (follow-up visit, 30-40 min): $150-200 reimbursement typically
• Initial evaluations (99205 or 90792): $250-350+
• Medication management visits: $100-180

See 20 patients per week via telehealth, average $150 per visit = $3,000/week gross or $144,000/year at 48 weeks.

Cash-pay:

• Initial ADHD evaluation: $300-500
• Follow-up medication management: $150-250

Cash-pay rates in major metros can be higher. At $200 per follow-up, 20 patients/week = $192,000/year gross revenue at 48 weeks.

Realistic schedule: Most providers on telehealth platforms start with 5-10 hours per week, seeing 10-15 patients, and scale from there based on demand and their availability.

Practical Steps: How to Start Prescribing ADHD Meds via Telehealth

1. Verify your state licensure and get additional licenses if needed

• If you want to see patients in multiple states, start the licensure process now (3-6 months in most states)
• Use IMLC if you’re a physician and it covers your target states
• Consider Florida’s out-of-state telehealth registration as a faster option

2. Obtain DEA registration in each state where you’ll prescribe

• This is separate from your license — you need a DEA number covering each state
• Register online at deadiversion.usdoj.gov
• Processing takes 4-8 weeks typically

3. Set up EPCS (Electronic Prescribing of Controlled Substances)

• Federal and state laws require e-prescribing for controlled substances in most cases
• Your EHR or telehealth platform should support EPCS — verify before you start
• You’ll need two-factor authentication (identity verification) to prescribe electronically

4. Register with state PDMPs

• Create provider accounts in each state’s PDMP system before you start prescribing
• Some states require this by law; others just expect you to use it
• Examples: California CURES, New York I-STOP, Florida E-FORCSE, Illinois AWARxE

5. Document your evaluation process

• Use a structured ADHD assessment template (symptom checklist, DSM-5 criteria, functional impairment, rule-outs)
• Document PDMP check in every chart where you prescribe stimulants
• Keep contemporaneous notes of video consultations (date/time, patient identity verified, clinical presentation, diagnosis, rationale for medication choice, informed consent)

6. Stay current on DEA rule changes

• Expect the DEA to publish permanent telemedicine regulations in late 2026
• Plan to obtain the new telemedicine special registration when it becomes available
• Monitor DEA announcements and update your practice protocols accordingly

7. Consider a platform vs going solo

• Solo practice: Full control, but you handle all marketing, scheduling, billing, compliance, and patient acquisition costs
• Telehealth platform: Lower risk, guaranteed patient flow, infrastructure handled, but you pay per appointment

For most providers, especially in the first year of telehealth ADHD care, a platform reduces risk and accelerates ramp-up time.

FAQs: Common Questions from Providers

Can I prescribe Adderall after just one video visit?
Yes, federally (through 2026) and in most states, if your evaluation meets the standard of care. You must use real-time video (not just a phone call or questionnaire), verify the patient’s identity, conduct a thorough ADHD assessment, check the PDMP, and document appropriately.

What if the DEA rules change in 2027?
The pending permanent rules will likely require a telemedicine special registration and mandatory nationwide PDMP checks, but will preserve the ability to prescribe via telehealth without an initial in-person visit. Expect transition time and guidance when the rules are published.

Do I need malpractice insurance that covers telehealth?
Yes. Most malpractice carriers now cover telehealth as standard, but verify your policy explicitly includes telemedicine and prescribing controlled substances via telehealth. If you’re working through a platform, ask if they provide malpractice coverage or require proof of your own.

Can I treat children with ADHD via telehealth?
Yes, in most states. Ensure parent/guardian consent and presence during the evaluation (required by law in many states for minors). Some states have specific telehealth consent rules for pediatric care — verify your state’s requirements. Clinically, video evaluation of children is effective if you adapt your approach (involve parents in symptom reporting, observe child behavior on screen, etc.).

What about prescribing to patients in multiple states?
You must be licensed in every state where your patient is physically located at the time of the visit. Multi-state licensure is common for telehealth providers, but requires planning (time, cost, DEA registrations in each state, PDMP registrations). Platforms often help streamline this by credentialing you in their focus states.

Are there prescribing limits for stimulants via telehealth?
Not under current federal rules. State rules vary — for example, Pennsylvania and Illinois NPs have 30-day limits on Schedule II prescriptions (if under collaboration), and New York allows up to 90-day prescriptions for ADHD. Check your state’s specific quantity limits.

What if a patient needs an in-person exam for some reason?
Build a referral network or have a plan for in-person follow-up if clinically indicated (e.g., complex medical comorbidities, need for physical exam, patient preference). Many telehealth practices partner with local clinics or refer to the patient’s PCP for any in-person needs.

Why Providers Are Choosing Klarity for ADHD Telehealth

You didn’t go into psychiatry to become a marketing expert or spend half your time chasing down patient leads. Klarity Health removes the friction that keeps most providers from scaling a telehealth practice:

Pre-qualified ADHD patients actively seeking care, matched to your availability and specialty. No wasted time on initial outreach or vetting calls.

Regulatory support to help you navigate multi-state licensing, DEA registrations, and state-specific prescribing rules. We keep you updated on changes (like the upcoming DEA permanent rules) so you don’t have to monitor federal registries.

Infrastructure handled — HIPAA-compliant video platform, e-prescribing integrated, scheduling, patient communication. You show up and practice medicine.

Flexible schedule — choose the hours and patient volume that fit your life. Start with 5 hours per week or build a full-time practice. You’re in control.

Both insurance and cash-pay options, depending on your preference and patient demographics. We handle insurance credentialing and billing if you choose to accept insurance.

Pay per appointment — no monthly fees, no upfront marketing spend. You only pay when a patient books and completes a visit. Guaranteed ROI.

If you’re interested in exploring Klarity’s provider network, visit our [provider signup page] or schedule a call with our provider relations team. We’re specifically looking for psychiatrists and PMHNPs who want to treat ADHD patients via telehealth in our priority states (California, Texas, Florida, New York, Pennsylvania, and Illinois), with expansion to additional states throughout 2026.

The Bottom Line

Telehealth ADHD care is legal, growing, and economically viable in 2026 — but only if you understand the regulatory landscape and structure your practice correctly.

Federal law allows telehealth prescribing of stimulants through 2026 under the current DEA extension, with permanent rules expected in 2027 that will preserve access while adding safeguards. State laws vary significantly: some (California, New York, Florida, Illinois) offer broad authority for both psychiatrists and experienced PMHNPs, while others (Texas, Pennsylvania) impose restrictions on NPs or require physician collaboration.

The real question isn’t whether telehealth ADHD care is legal — it’s whether you want to handle patient acquisition, compliance, and infrastructure yourself or partner with a platform that removes those headaches so you can focus on clinical care.

For most providers, especially those scaling into telehealth for the first time, a platform model makes economic sense. You eliminate the risk of failed marketing campaigns, reduce administrative overhead, and guarantee patient flow — all while maintaining clinical autonomy and controlling your schedule.

The ADHD treatment gap isn’t going away. Patients are searching for providers right now. The regulatory pathway is clear. The only question is whether you’re going to capture that opportunity — or let it pass while you’re waiting for ‘perfect’ clarity that will never come.

Ready to start? [Join Klarity’s provider network] or [schedule a consultation call] to discuss how we can support your telehealth ADHD practice.

Sources and References

The following sources were consulted for regulatory information in this guide. All details have been verified against the most current available information as of February 2026.

1. DEA & HHS Press Release – Extension of Telemedicine Flexibilities Through 2026 (January 2, 2026)
   Official government announcement of the fourth extension of telehealth prescribing flexibilities for controlled substances through December 31, 2026.
   HHS.gov | Healthcare Dive coverage

2. DEA Press Release – Three New Telemedicine Rules (January 16, 2025)
   DEA announcement previewing permanent telemedicine regulations, including special registration requirements and PDMP mandates.
   DEA.gov

3. Texas Board of Nursing – APRN Practice FAQ
   Official guidance on nurse practitioner prescribing authority in Texas, including Schedule II restrictions.
   Texas BON

4. Florida Statutes §456.47 (Telehealth) and §464.012 (APRN Prescribing)
   Primary legal text of Florida laws governing telehealth prescribing and nurse practitioner authority.
   Florida Legislature

5. New York State Department of Health – Bureau of Narcotic Enforcement Guidance (May 21, 2025)
   Official state guidance on prescribing controlled substances via telehealth, aligning New York law with federal allowances.
   Ninth Judicial District summary

6. Pennsylvania Code – CRNP Prescriptive Authority Regulations (49 Pa. Code Chapter 21)
   Official administrative code detailing nurse practitioner prescribing limits in Pennsylvania, including 30-day Schedule II restriction.
   PA Code and Bulletin

7. Illinois Administrative Code – Nurse Practice Act Rules (68 Ill. Adm. Code 1300)
   State regulations governing APRN practice, collaboration requirements, and Full Practice Authority pathway.
   Illinois General Assembly

8. California Business & Professions Code §2242 and §4067
   Primary California law confirming telehealth examinations satisfy prescribing requirements.
   Summarized by Center for Connected Health Policy

9. RxAgent – NP Prescriptive Authority by State Guide (Updated December

Source:

• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,II%20to%20Schedule%20V%20drugs
• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,to%20hash%20out%20permanent%20regulations
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Proposed%20DEA%20rules%20create%20a,for%20telemedicine%20prescribing
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=there%20any%20settings%20other%20than,may%20prescribe%20Schedule%20II%20controlled
• https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth#:~:text=as%20such%20terms%20are%20defined,the%20use%20of%20electronic%20prescribing
• https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html#:~:text=,
• https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300#:~:text=match%20at%20L5536%203,collaborating%20physician%20or%20podiatric%20physician
• https://rxagent.co/blog/np-prescribing-authority#:~:text=However%2C%20,3
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Prescribing%2C%20dispensing%2C%20or%20furnishing%20dangerous,the%20appropriate%20standard%20of%20care